1. Home
  2. CBU vs ERAS Comparison

CBU vs ERAS Comparison

Compare CBU & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBU

Community Bank System Inc.

HOLD

Current Price

$61.91

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$13.90

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBU
ERAS
Founded
1866
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
4.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
CBU
ERAS
Price
$61.91
$13.90
Analyst Decision
Hold
Strong Buy
Analyst Count
4
12
Target Price
$66.67
$14.25
AVG Volume (30 Days)
248.3K
4.8M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
3.02%
N/A
EPS Growth
15.41
36.23
EPS
1.08
N/A
Revenue
$818,007,000.00
N/A
Revenue This Year
$13.46
N/A
Revenue Next Year
$7.75
N/A
P/E Ratio
$57.35
N/A
Revenue Growth
9.61
N/A
52 Week Low
$51.12
$1.24
52 Week High
$67.50
$24.28

Technical Indicators

Market Signals
Indicator
CBU
ERAS
Relative Strength Index (RSI) 43.74 55.49
Support Level $60.93 $12.36
Resistance Level $64.83 $15.58
Average True Range (ATR) 1.61 1.14
MACD -0.29 0.19
Stochastic Oscillator 18.92 66.36

Price Performance

Historical Comparison
CBU
ERAS

About CBU Community Bank System Inc.

Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: